| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| José Baselg. Why the epidermal growth factor receptor? The rationale for cancer therapy. The oncologist. vol 7 Suppl 4. 2002-11-21. PMID:12202782. |
activation of the egfr signaling pathway in cancer cells has been linked with increased cell proliferation, angiogenesis, and metastasis, and decreased apoptosis. |
2002-11-21 |
2023-08-12 |
Not clear |
| Carlos L Arteag. Epidermal growth factor receptor dependence in human tumors: more than just expression? The oncologist. vol 7 Suppl 4. 2002-11-21. PMID:12202786. |
egfr signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis. |
2002-11-21 |
2023-08-12 |
human |
| Yi Wang, Steven Pennock, Xinmei Chen, Zhixiang Wan. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Molecular and cellular biology. vol 22. issue 20. 2002-10-30. PMID:12242303. |
by using this system, we provided original evidence demonstrating that (i) the endosome can serve as a nucleation site for the formation of signaling complexes, (ii) endosomal egfr signaling is sufficient to activate the major signaling pathways leading to cell proliferation and survival, and (iii) endosomal egfr signaling is sufficient to suppress apoptosis induced by serum withdrawal. |
2002-10-30 |
2023-08-12 |
Not clear |
| Karoly Toth, Mohan Kuppuswamy, Konstantin Doronin, Oksana Doronina, Drew Lichtenstein, Ann Tollefson, William Wol. Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region. Virology. vol 301. issue 1. 2002-10-18. PMID:12359450. |
the rid-expressing vectors forced the internalization and degradation of fas and egfr, and they inhibited apoptosis induced through the fas pathway. |
2002-10-18 |
2023-08-12 |
Not clear |
| Yuya Yoshimoto, Masaya Imot. Induction of EGF-dependent apoptosis by vacuolar-type H(+)-ATPase inhibitors in A431 cells overexpressing the EGF receptor. Experimental cell research. vol 279. issue 1. 2002-09-30. PMID:12213220. |
the egf-dependent apoptosis by v-atpase inhibitors was not observed in other types of human tumor cells which do not overexpress egfr. |
2002-09-30 |
2023-08-12 |
human |
| Wenle Xia, Robert J Mullin, Barry R Keith, Lei-Hua Liu, Hong Ma, David W Rusnak, Gary Owens, Krystal J Alligood, Neil L Specto. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. vol 21. issue 41. 2002-09-19. PMID:12214266. |
here we show that a small molecule, gw572016, potently inhibits both egfr and erbb2 tyrosine kinases leading to growth arrest and/or apoptosis in egfr and erbb2-dependent tumor cell lines. |
2002-09-19 |
2023-08-12 |
human |
| Arnab Chakravarti, Abhijit Chakladar, Meaghan A Delaney, Douglas E Latham, Jay S Loeffle. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer research. vol 62. issue 15. 2002-09-11. PMID:12154034. |
inhibition of either egfr or ras activity appears to not only abrogate the observed antagonism between sequentially administered radiation and chemotherapy but actually results in a greater enhancement of apoptosis in the setting of combined modality therapy than when administered with either radiation or chemotherapy as single agents. |
2002-09-11 |
2023-08-12 |
human |
| Vivian Wai Yan Lui, Jennifer Rubin Grandi. EGFR-mediated cell cycle regulation. Anticancer research. vol 22. issue 1A. 2002-06-25. PMID:12017269. |
specific abrogation of egfr results in cell cycle arrest, apoptosis, or dedifferentiaton of cancer cells. |
2002-06-25 |
2023-08-12 |
human |
| Joachim P Steinbach, Petra Supra, H-J Su Huang, Webster K Cavenee, Michael Welle. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain pathology (Zurich, Switzerland). vol 12. issue 1. 2002-05-30. PMID:11770895. |
these data define a modulatory effect of egfr-activity on death ligand-induced apoptosis and indicate that egfr inhibition is likely to improve the efficacy of death ligand-based cancer therapies. |
2002-05-30 |
2023-08-12 |
human |
| Joachim P Steinbach, Petra Supra, H-J Su Huang, Webster K Cavenee, Michael Welle. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain pathology (Zurich, Switzerland). vol 12. issue 1. 2002-05-30. PMID:11770895. |
furthermore, it is tempting to speculate that egfr amplification protects tumor cells from death ligand-mediated host immune responses in vivo and that egfr's effects on death receptor-mediated apoptosis may explain the anti-tumor effects of non-cytotoxic, unarmed anti-egfr family antibodies. |
2002-05-30 |
2023-08-12 |
human |
| Fortunato Ciardiello, Rosa Caputo, Gaetano Borriello, Donatella Del Bufalo, Annamaria Biroccio, Gabriella Zupi, A Raffaele Bianco, Giampaolo Tortor. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International journal of cancer. vol 98. issue 3. 2002-04-16. PMID:11920601. |
to determine whether the blockade of egfr signaling might affect the sensitivity of bcl-2-overexpressing mcf-7 adr cells to taxanes, cells were treated with zd1839 in combination with paclitaxel, docetaxel or idn 5109, and dose-dependent cooperative growth inhibition as well as apoptosis potentiation were observed. |
2002-04-16 |
2023-08-12 |
human |
| Andreas Bergmann, Michael Tugentman, Ben Zion Shilo, Hermann Stelle. Regulation of cell number by MAPK-dependent control of apoptosis: a mechanism for trophic survival signaling. Developmental cell. vol 2. issue 2. 2002-03-12. PMID:11832242. |
in midline glia that fail to activate the egfr pathway, hid induces apoptosis by blocking a caspase inhibitor, diap1. |
2002-03-12 |
2023-08-12 |
drosophila_melanogaster |
| Kai C Chan, W Fiona Knox, Julia M Gee, Julie Morris, Robert I Nicholson, Christopher S Potten, Nigel J Bundre. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer research. vol 62. issue 1. 2002-02-12. PMID:11782368. |
the purpose of this study was to establish whether the egfr tyrosine kinase inhibitor (egfr-tki), zd1839 (iressa), can reduce epithelial proliferation and increase apoptosis in egfr-positive dcis. |
2002-02-12 |
2023-08-12 |
Not clear |
| Arnab Chakravarti, Jay S Loeffler, Nicholas J Dyso. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer research. vol 62. issue 1. 2002-02-12. PMID:11782378. |
cotargeting igfr-i with egfr greatly enhanced both spontaneous and radiation-induced apoptosis of the gbm(r) cells and reduced their invasive potential. |
2002-02-12 |
2023-08-12 |
human |
| P M Harari, S M Huan. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Seminars in radiation oncology. vol 11. issue 4. 2001-12-07. PMID:11677653. |
although the initial impetus for examining egfr signal interruption as an anticancer strategy involved proliferative growth inhibition, more recent studies now confirm the capacity of egfr down-regulation to modify apoptosis, invasion capacity, angiogenesis, dna damage repair, and cellular response to radiation and selected chemotherapy agents. |
2001-12-07 |
2023-08-12 |
human |
| F Ciardiello, G Tortor. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 7. issue 10. 2001-12-05. PMID:11595683. |
the epidermal growth factor receptor (egfr) autocrine pathway contributes to a number of processes important to cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread. |
2001-12-05 |
2023-08-12 |
Not clear |
| L Qiao, E Studer, K Leach, R McKinstry, S Gupta, R Decker, R Kukreja, K Valerie, P Nagarkatti, W El Deiry, J Molkentin, R Schmidt-Ullrich, P B Fisher, S Grant, P B Hylemon, P Den. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Molecular biology of the cell. vol 12. issue 9. 2001-12-04. PMID:11553704. |
deoxycholic acid (dca) causes ligand-independent activation of epidermal growth factor receptor (egfr) and fas receptor in primary hepatocytes: inhibition of egfr/mitogen-activated protein kinase-signaling module enhances dca-induced apoptosis. |
2001-12-04 |
2023-08-12 |
Not clear |
| J Barton, G Blackledge, A Wakelin. Growth factors and their receptors: new targets for prostate cancer therapy. Urology. vol 58. issue 2 Suppl 1. 2001-10-25. PMID:11502465. |
stimulation of the signal transduction pathway of the epidermal growth-factor receptor (egfr) tyrosine kinase family of receptors in tumor cells enhances cellular proliferation, prevents apoptosis, and promotes tumor-cell mobility, adhesion, and invasion. |
2001-10-25 |
2023-08-12 |
Not clear |
| H H Sedlace. Mechanisms of action of flavopiridol. Critical reviews in oncology/hematology. vol 38. issue 2. 2001-09-13. PMID:11311660. |
however, no in situ data from flavopiridol treated cells have been published yet that prove that by inhibition of egfr, pp60 src, pkc and/or erk-1 (in addition to inhibition of cdk's) flavopiridol is able to induce apoptosis. |
2001-09-13 |
2023-08-12 |
Not clear |
| N Ahmad, K Kalka, H Mukhta. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene. vol 20. issue 18. 2001-06-21. PMID:11402326. |
pc4-pdt was found to result in a time-dependent: (i) inhibition of protein expressions of egfr; and (ii) tyrosine phosphorylation of egfr and shc; and (iii) induction of apoptosis, during the regression of these tumors. |
2001-06-21 |
2023-08-12 |
mouse |